Psychiatry and Clinical Psychopharmacology
Editorial

Comment on FDA’s Breakthrough Therapy Designation of Intranasal Esketamine for the Treatment of Major Depressive Disorder with Imminent Risk of Suicide

1.

Professor of Psychiatry & Neuroscience, Neurochemical Research Unit, Department of Psychiatry and Neuroscience and Mental Health Institute, University of Alberta, Edmonton, AB, Canada.

2.

Professor of Psychiatry, Editor in Chief, Bulletin of Clinical Psychopharmacology, Honorary President of Turkish Association for Psychopharmacology & General Secretary of Turkish Association for Psychopharmacology, Istanbul, Turkey.

Psychiatry and Clinical Psychopharmacology 2016; 26: 329-331
DOI: 10.5455/bcp.20161027122045
Read: 702 Downloads: 524 Published: 22 January 2021
Files
EISSN 2475-0581